Opportunity
SAM #36C26026Q0957
VA Portland seeks multiplex PCR molecular diagnostic kits (GI, ME, RP 2.1, BCID2 panels)
Buyer
Vanco 20
Posted
August 18, 2026
Respond By
September 12, 2026
Identifier
36C26026Q0957
NAICS
325413
The Department of Veterans Affairs, Portland Veterans Affairs Medical Center, is seeking molecular diagnostic laboratory reagents (kits) for multiplex PCR testing. - Government Buyer: - Department of Veterans Affairs, Veterans Health Administration, Portland Veterans Affairs Medical Center - Products Requested: - Molecular Testing Kits for GI panel, ME panel, RP 2.1 panel, and BCID2 panel - Quantities per year (base and each option period): - GI panel: 892 kits - ME panel: 51 kits - RP 2.1 panel: 628 kits - BCID2 panel: 329 kits - Total contract period includes base plus four option years - Technical Requirements: - Kits must be compatible with VA-owned molecular analyzers - Multiplex PCR method required - FDA-cleared assays capable of: - Simultaneously testing up to 20 respiratory pathogen targets - At least 20 gastrointestinal pathogen targets (viruses, bacteria, parasites) - At least 40 blood culture identification targets - Up to 14 meningitis/encephalitis targets (bacteria, viruses, fungi) - Minimal hands-on setup time (2 minutes or less) - Results delivered within one hour - Self-contained system for amplification, detection, and analysis - Software must automatically generate a result for each target in a single report - OEMs and Vendors: - No specific OEMs or vendors named, but likely manufacturers include bioMérieux, Luminex, and Cepheid - Notable Requirements: - Kits must be FDA-cleared and compatible with VA molecular analyzers - NAICS code: 325413 (In-Vitro Diagnostic Substance Manufacturing)
Description
Vendor will provide Test Kits as needed to perform testing on VA owned molecular analyzer, located in the VA Portland Medical Center Microbiology Department.
The instrument processes kits that must utilize a multiplex PCR (polymerase chain reaction) method, have FDA-cleared assays that simultaneously tests for as many as 20 respiratory pathogen targets, has testing capability to test for common GI pathogens including viruses, bacteria, and parasites with at least 20 targets, at least 40 blood culture identification targets, and up to 14 meningitis/encephalitis targets inclusive of bacteria, viruses and fungi.
The method should have very little hands-on time (2 minutes or less) to set up and have results for respiratory pathogen targets, blood culture, GI pathogens and meningitis/encephalitis targets in one hour. The technique must perform amplification, detection and analysis in one self-contained system. The VA equipment includes software that automatically generates a result for each target in a single report.